{"owner": "ArrayExpress Uploader", "ownerprofile_id": "arrayexpress_sid", "species": "human", "factors": [{"CIT-HS-NATL-PG-S01": {"SampleType": "tissue", "Age": "68", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S02": {"SampleType": "tissue", "Age": "71", "DiseaseStage": "3", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S03": {"SampleType": "tissue", "Age": "53", "DiseaseStage": "n/a", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S04": {"SampleType": "tissue", "Age": "59", "DiseaseStage": "n/a", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S05": {"SampleType": "tissue", "Age": "65", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S06": {"SampleType": "tissue", "Age": "50", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S07": {"SampleType": "tissue", "Age": "74", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S08": {"SampleType": "tissue", "Age": "75", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S09": {"SampleType": "tissue", "Age": "81", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S10": {"SampleType": "tissue", "Age": "53", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S11": {"SampleType": "tissue", "Age": "64", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S12": {"SampleType": "tissue", "Age": "71", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S13": {"SampleType": "tissue", "Age": "69", "DiseaseStage": "3", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S14": {"SampleType": "tissue", "Age": "83", "DiseaseStage": "n/a", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S02": {"SampleType": "tissue", "Age": "71", "DiseaseStage": "3", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S16": {"SampleType": "tissue", "Age": "81", "DiseaseStage": "n/a", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S17": {"SampleType": "tissue", "Age": "67", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S17C": {"SampleType": "sorted cells", "Age": "  ", "DiseaseStage": "n/a", "Age(years)": "n/a", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S18C": {"SampleType": "sorted cells", "Age": "54", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "angioimmunoblastic T-cell lymphoma"}}, {"CIT-HS-NATL-PG-S19": {"SampleType": "tissue", "Age": "21", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S20": {"SampleType": "tissue", "Age": "69", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S21": {"SampleType": "tissue", "Age": "45", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S22": {"SampleType": "tissue", "Age": "77", "DiseaseStage": "3", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S23": {"SampleType": "tissue", "Age": "59", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S24": {"SampleType": "tissue", "Age": "69", "DiseaseStage": "1", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S25": {"SampleType": "tissue", "Age": "63", "DiseaseStage": "3", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S26": {"SampleType": "tissue", "Age": "32", "DiseaseStage": "3", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S27": {"SampleType": "tissue", "Age": "56", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S28": {"SampleType": "tissue", "Age": "62", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S29": {"SampleType": "tissue", "Age": "57", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S30": {"SampleType": "tissue", "Age": "66", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S31": {"SampleType": "tissue", "Age": "35", "DiseaseStage": "1", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S32": {"SampleType": "tissue", "Age": "67", "DiseaseStage": "3", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S33": {"SampleType": "tissue", "Age": "42", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}, {"CIT-HS-NATL-PG-S34": {"SampleType": "tissue", "Age": "54", "DiseaseStage": "4", "Age(years)": "  ", "DiseaseState": "peripheral T-cell lymphoma, not otherwise specified"}}], "id": 5247, "pop_total": 0, "platform": 4, "summary_wrapped": "[u'A \\uff91Cartes d\\uff92Identite des Tumeurs\\uff92 (CIT) project from the french Ligue Nationale Contre le Cancer (', {u'a': {u'href':...", "pubmed_id": 17284527, "geo_gse_id": "E-TABM-783", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 5, "sample_count": 35, "tags": ["cancer", "cell", "dendritic", "follicular dendritic cell", "lymphoma", "peripheral", "peripheral t-cell lymphoma"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "transcription-profiling-of-human-non-anaplastic-t", "geo_id_plat": "E-TABM-783_A-AFFY-44", "name": "Transcription profiling of human non anaplastic T-cell lymphoma", "created": "Sep.22, 2014", "summary": "[u'A \\uff91Cartes d\\uff92Identite des Tumeurs\\uff92 (CIT) project from the french Ligue Nationale Contre le Cancer (', {u'a': {u'href': u'http://cit.ligue-cancer.net', u'target': u'_blank', u'$': u'http://cit.ligue-cancer.net'}}, u') | Affymetrix HG-U133 Plus 2.0 : 17 AITL biopsies, 2 AITL sorted cells, 16 PTCL NOS biopsies | The molecular alterations underlying the pathogenesis of angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma, unspecified (PTCL-u) are largely unknown. In order to characterize the ontogeny and molecular differences between both entities, a series of AITLs (n = 18) and PTCLs-u (n = 16) was analyzed using gene expression profiling. Unsupervised clustering correlated with the pathological classification and with CD30 expression in PTCL-u. The molecular profile of AITLs was characterized by a strong microenvironment imprint (overexpression of B-cell- and follicular dendritic cell-related genes, chemokines, and genes related to extracellular matrix and vascular biology), and overexpression of several genes characteristic of normal follicular helper T (T(FH)) cells (CXCL13, BCL6, PDCD1, CD40L, NFATC1). By gene set enrichment analysis, the AITL molecular signature was significantly enriched in published T(FH)-specific genes. The enrichment was higher for sorted AITL cells than for tissue samples. Overexpression of several T(FH) genes was validated by immunohistochemistry in AITLs. A few cases with molecular T(FH)-like features were identified among CD30(-) PTCLs-u. Our findings strongly support that T(FH) cells represent the normal counterpart of AITL, and suggest that the AITL spectrum may be wider than suspected, as a subset of CD30(-) PTCLs-u may derive from or be related to AITL.| Submitter : Aurelien de Reynies <reyniesa@ligue-cancer.fr> | Project leader : Philippe Gaulard <philippe.gaulard@hmn.aphp.fr>']", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-783", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-783/samples/"}